The American College of Cardiology (ACC) Statin Intolerance App is now available to help guide clinicians through the process of managing and treating patients who report muscle symptoms while on statin therapy.

Medtronic, CardioInsight, acquisition, ECVUE, cardiac mapping system

Medtronic has acquired CardioInsight Technologies Inc., a Cleveland-based medical device company that has developed a new approach to improve the mapping of electrical disorders of the heart. CardioInsight will become part of the Medtronic atrial fibrillation solutions business in the cardiac rhythm and heart failure division.

SentreHeart Inc. announced that it has received approval for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in a clinical study of the Lariat Suture Delivery Device. The randomized, controlled clinical study, known as the AMAZE Trial, will evaluate the use of the Lariat device for the ligation, or closure, of the left atrial appendage (LAA) as an adjunctive treatment to ablation in patients with persistent or longstanding persistent atrial fibrillation (AFib).

CardiAQ Valve Technologies, TMVI, second generation, implantation, Tor Vergata

CardiAQ Valve Technologies (CardiAQ) announced that its second-generation transcatheter bioprosthetic mitral heart valve was successfully implanted as a compassionate treatment. The device was placed into a 72-year-old male suffering from severe mitral regurgitation (MR 4+) with multiple co-morbidities and ineligible for alternate treatment modalities.
REDUCE FMR, Cardiac Dimensions, Carillon Mitral Contour System, FMR

Cardiac Dimensions announced the first patients have been enrolled in the REDUCE FMR clinical trial. REDUCE FMR is a prospective, double-blind, randomized multi-center trial, evaluating the company’s minimally-invasive Carillon Mitral Contour System.
ACC, HRS, SCAI, left atrial appendage occlusion, recommendations

The American College of Cardiology (ACC), Heart Rhythm Society (HRS) and Society for Cardiovascular Angiography and Interventions (SCAI) released a new overview on the implantation of left atrial appendage occlusion devices.

Merge Healthcare Inc. announced that it has entered into a strategic partnership with Toshiba America Medical Systems, Inc. Under this new agreement, Toshiba will be able to offer its customers a full turnkey solution, combining Merge's cardiology picture archiving and communication system (PACS) and hemodynamic monitoring solutions with the Toshiba portfolio of vascular X-ray systems.

Sunshine Heart Inc. has borrowed an additional $2 million to continue work on its U.S. pivotal study for the C-Pulse Heart Assist System. The minimally invasive surgically implanted device is designed to reduce and potentially reverse heart failure symptoms.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now